MRT-51443 / Monte Rosa Therap - LARVOL DELTA

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer (GlobeNewswire) - "Summary of findings: MRT-51443 exhibited potency, selectivity, and favorable drug-like properties; MRT-51443 demonstrated superior selectivity as compared to several clinical-stage small molecule CDK2 inhibitors; In cellular assays, MRT-51443 induced deep CDK2 degradation, resulting in CDK2-dependent cancer cell growth inhibition; MRT-51443 in combination with CDK4/6 inhibition and anti-estrogen therapy drove deep tumor regressions and achieved superior tumor regression compared to standard of care CDK4/6 inhibition and anti-estrogen therapy in HR+/HER2- breast cancer models; Specifically, in the MCF7 model, the combination of MRT-51443 + ribociclib + fulvestrant demonstrated median tumor growth of -77% versus -3% for ribociclib + fulvestrant. In the T47D model, MRT-51443 + ribociclib + fulvestrant demonstrated median tumor growth of -61% versus -10% for ribociclib + fulvestrant."

Preclinical • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer